Radiomics­Clinical model based on 99mTc-MDP SPECT/CT for distinguishing between bone metastasis and benign bone disease in tumor patients.

ABSTRACT

BACKGROUND: To establish a radiomics-clinical model based on 99mTc-MDP SPECT/CT for distinguishing between bone metastasis and benign bone disease in tumor patients. METHODS: We retrospectively analyzed 256 patients (122 with bone metastasis and 134 with benign bone disease) and randomized them in the ratio of 622 into training, test and validation sets. All patients underwent 99mTc-labeled methylene diphosphonate (99mTc-MDP) SPECT/CT. We manually outlined the volumes of interest (VOIs) of lesions using ITK-SNAP from SPECT and CT images. In the training set, radiomics features were extracted using PyRadiomics and selected using Least Absolute Shrinkage and Selection Operator (LASSO) regression. Then, we established three radiomics models (CT, SPECT and SPECT-CT models) using support vector machine (SVM). In addition, a radiomics-clinical model was constructed using multivariable logistic regression analysis. The four models' performance was assessed using the area under the receiver operating characteristic curve (AUC). Using DeLong test to make comparisons between the ROC (receiver operating characteristic) curves of different models. The clinical utility of the models was evaluated using decision curve analysis (DCA). RESULTS: The radiomics-clinical displayed excellent performance, and its AUC was 0.941 and 0.879 in the training and test sets. The DCA of radiomics-clinical model showed the highest clinical utility. CONCLUSIONS: The radiomics-clinical nomogram for identifying bone metastasis and benign bone disease in tumor patients was suitable to assist in clinical decision.